CA2649701A1 - Use of organic compounds - Google Patents

Use of organic compounds Download PDF

Info

Publication number
CA2649701A1
CA2649701A1 CA002649701A CA2649701A CA2649701A1 CA 2649701 A1 CA2649701 A1 CA 2649701A1 CA 002649701 A CA002649701 A CA 002649701A CA 2649701 A CA2649701 A CA 2649701A CA 2649701 A1 CA2649701 A1 CA 2649701A1
Authority
CA
Canada
Prior art keywords
disease
diabetes
agonist
err
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002649701A
Other languages
English (en)
French (fr)
Inventor
Shamina M. Rangwala
Susan C. Stevenson
Zhidan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38477124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2649701(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2649701A1 publication Critical patent/CA2649701A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002649701A 2006-05-03 2007-05-02 Use of organic compounds Abandoned CA2649701A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79722806P 2006-05-03 2006-05-03
US60/797,228 2006-05-03
PCT/US2007/067971 WO2007131005A2 (en) 2006-05-03 2007-05-02 Use of organic compounds

Publications (1)

Publication Number Publication Date
CA2649701A1 true CA2649701A1 (en) 2007-11-15

Family

ID=38477124

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002649701A Abandoned CA2649701A1 (en) 2006-05-03 2007-05-02 Use of organic compounds

Country Status (13)

Country Link
US (1) US20090281191A1 (de)
EP (1) EP2015777B1 (de)
JP (1) JP2009535425A (de)
KR (1) KR20090005137A (de)
CN (1) CN101432024A (de)
AT (1) ATE477819T1 (de)
AU (1) AU2007248112A1 (de)
BR (1) BRPI0711174A2 (de)
CA (1) CA2649701A1 (de)
DE (1) DE602007008553D1 (de)
MX (1) MX2008014008A (de)
RU (1) RU2008147269A (de)
WO (1) WO2007131005A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5935030B2 (ja) 2010-05-14 2016-06-15 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 白血病を治療するための組成物および方法
WO2011143657A1 (en) 2010-05-14 2011-11-17 Dana-Farber Cancer Institute, Inc. Male contraceptive compositions and methods of use
HUE031073T2 (en) 2010-05-14 2017-06-28 Dana Farber Cancer Inst Inc Thieno triazolo-diazepine compounds for the treatment of neoplasia
US8962546B2 (en) 2011-03-01 2015-02-24 Salk Institute For Biological Studies Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2014159392A1 (en) 2013-03-14 2014-10-02 Dana-Farber Cancer Institute, Inc. Bromodomain binding reagents and uses thereof
WO2014205045A1 (en) * 2013-06-18 2014-12-24 Downes, Michael Methods of treating muscular dystrophy
BR112016001457A2 (pt) 2013-07-25 2017-08-29 Dana Farber Cancer Inst Inc Inibidores de fatores de transcrição e usos dos mesmos
MX2016005980A (es) 2013-11-08 2016-12-09 Dana Farber Cancer Inst Inc Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
CA2936865A1 (en) 2014-01-31 2015-08-06 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2017504650A (ja) 2014-01-31 2017-02-09 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ジアゼパン誘導体およびその使用
MX2016011160A (es) 2014-02-28 2017-04-27 Tensha Therapeutics Inc Tratamiento de afecciones asociadas con la hiperinsulinemia.
MX2017001757A (es) 2014-08-08 2017-05-30 Dana Farber Cancer Inst Inc Derivados de dihidropteridinona y sus usos.
WO2016022902A1 (en) 2014-08-08 2016-02-11 Dana-Farber Cancer Institute, Inc. Diazepane derivatives and uses thereof
PE20171042A1 (es) 2014-10-27 2017-07-19 Tensha Therapeutics Inc Inhibidores del bromodominio
JP6495468B2 (ja) 2015-02-27 2019-04-03 ソーク インスティチュート フォー バイオロジカル スタディーズ リプログラミング前駆体組成物およびその使用方法
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
KR20180051576A (ko) 2015-09-11 2018-05-16 다나-파버 캔서 인스티튜트 인크. 아세트아미드 티에노트리아졸로디아제핀 및 그의 용도
MX2018003031A (es) 2015-09-11 2018-08-01 Dana Farber Cancer Inst Inc Ciano tienotriazolpirazinas y usos de las mismas.
WO2017053084A1 (en) * 2015-09-25 2017-03-30 Salk Institute For Biological Studies Estrogen related receptor gamma (erry) enhances and maintains brown fat thermogenic capacity
SG11201803210YA (en) 2015-11-25 2018-05-30 Dana Farber Cancer Inst Inc Bivalent bromodomain inhibitors and uses thereof
AU2017269364B2 (en) 2016-05-25 2023-08-31 Salk Institute For Biological Studies Compositions and methods for organoid generation and disease modeling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005514921A (ja) * 2001-11-09 2005-05-26 ダナ−ファーバー キャンサー インスティチュート インク ＰＧＣ−１β、新規ＰＧＣ−１相同体およびその用途
EP1548434A4 (de) * 2002-08-08 2007-05-09 Japan Science & Tech Agency Verfahren zum screening eines medikaments
US20050074765A1 (en) * 2002-10-16 2005-04-07 Blanchard Steven G. Methods for identifying and using modulators of estrogen related receptor gamma
WO2006130503A2 (en) * 2005-05-27 2006-12-07 Janssen Pharmaceutica N.V. Errϝ peptide fragment complexes and uses thereof in drug discovery

Also Published As

Publication number Publication date
JP2009535425A (ja) 2009-10-01
EP2015777A2 (de) 2009-01-21
AU2007248112A1 (en) 2007-11-15
DE602007008553D1 (de) 2010-09-30
BRPI0711174A2 (pt) 2011-08-23
KR20090005137A (ko) 2009-01-12
EP2015777B1 (de) 2010-08-18
WO2007131005A2 (en) 2007-11-15
CN101432024A (zh) 2009-05-13
MX2008014008A (es) 2009-03-25
US20090281191A1 (en) 2009-11-12
RU2008147269A (ru) 2010-06-10
WO2007131005A3 (en) 2008-06-19
ATE477819T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
US20090281191A1 (en) Use of organic compounds
Song et al. Abnormal kynurenine pathway of tryptophan catabolism in cardiovascular diseases
Li et al. Vascular insulin resistance in prehypertensive rats: role of PI3-kinase/Akt/eNOS signaling
Caldwell et al. Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51
Consitt et al. Peroxisome proliferator–activated receptor-γ coactivator-1α overexpression increases lipid oxidation in myocytes from extremely obese individuals
Zhou et al. Melatonin inhibits glucose-induced apoptosis in osteoblastic cell line through PERK-eIF2α-ATF4 pathway
Baer et al. Panic attacks and the dexamethasone suppression test
US8058316B2 (en) STAT3 inhibiting compositions and methods
Ding et al. Insulin resistance disrupts the interaction between AKT and the NMDA receptor and the inactivation of the CaMKIV/CREB pathway in minimal hepatic encephalopathy
Tanis et al. The effect of glucose concentration and sodium phenylbutyrate treatment on mitochondrial bioenergetics and ER stress in 3T3-L1 adipocytes
Brown et al. The APOE4 genotype alters the response of microglia and macrophages to 17β-estradiol
Li et al. HIGD1A links SIRT1 activity to adipose browning by inhibiting the ROS/DNA damage pathway
Pei et al. Downregulation of chemerin and alleviation of endoplasmic reticulum stress by metformin in adipose tissue of rats
JP2005523004A (ja) グルコース取り込みの増加及びｉｉ型糖尿病の治療のためのｎａｄ（ｐ）ｈオキシダーゼ阻害剤
JP5901770B2 (ja) Ｃｙｐ４ａ阻害剤を有効成分として含有する糖尿病又は脂肪肝の予防又は治療用薬学的組成物。
Xiao et al. Mitochondrial energetic impairment in a patient with late‐onset glutaric acidemia Type 2
Gao et al. Oxidative stress increases the risk of pancreatic β cell damage in chronic renal hypertensive rats
Wang et al. Teneligliptin alleviates diabetes-related cognitive impairment by inhibiting the endoplasmic reticulum (ER) stress and NLRP3 inflammasome in mice
WO2010007085A2 (en) Use of organic compounds
Wang et al. Insulin and adipokine signaling and their cross-regulation in postmortem human brain
US20170087145A1 (en) Gapdh cascade inhibitor compounds and methods of use and treatment of stress induced disorders including mental illness
WO2005085846A1 (ja) 虚血性心疾患危険群診断薬
Kasuno et al. Urinary thioredoxin as a biomarker of renal redox dysregulation and a companion diagnostic to identify responders to redox-modulating therapeutics
US10376484B2 (en) Combination of bezafibrate and of resveratrol or resveratrol derivatives for the treatment and prevention of diseases involving a mitochondrial energy dysfunction
Tvarijonaviciute et al. Serum adiponectin concentration in dogs—absence of diurnal variation and lack of effect of feeding and methylprednisolone administration

Legal Events

Date Code Title Description
FZDE Discontinued